REXAHN PHARMACEUTICALS, INC. DEF 14A 6-11-2007

Company

Opus Genetics, Inc.

Filed

May 16, 2007

Period of Report

June 11, 2007

Accession Number

0001140361-07-010103

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →